Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs

Experimental Hematology

Volumn 34, Issue 6, 2006, Pages 728-735

  Nguyen, Dzung H ^a,b   Ball, Edward D ^b,c   Varki, Ajit ^a,b,c  

^a University of California San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CELL SURFACE PROTEIN; PROTEIN SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTINS 10; PROTEIN SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTINS 5; PROTEIN SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTINS 6; PROTEIN SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTINS 7; PROTEIN SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTINS 9; SAPORIN; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN BINDING; ARTICLE; CANCER CELL; CELL KILLING; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC CAPPING; IMMUNOTOXINS; LECTINS; LEUKEMIA, MYELOID; MYELOID PROGENITOR CELLS; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; TUMOR STEM CELLS; U937 CELLS;

EID: 33646706126     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.03.003     Document Type: Article

References (32)

1. Crocker P.R., and Varki A. Siglecs in the immune system. Immunology 103 (2001) 137-145
2. Crocker P.R. Siglecs in innate immunity. Curr Opin Pharmacol 5 (2005) 431-437
3. Varki A., and Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 16 (2006) 1R-27R
4. Ikehara Y., Ikehara S.K., and Paulson J.C. Negative regulation of T cell receptor signaling by Siglec-7 (p70/airm) and Siglec-9. J Biol Chem 279 (2004) 43117-43125
5. van Lochem E.G., van der Velden V.H., Wind H.K., te Marvelde J.G., Westerdaal N.A., and van Dongen J.J. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry 60B (2004) 1-13
6. Tanimoto M., Scheinberg D.A., Cordon-Cardo C., Huie D., Clarkson B.D., and Old L.J. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody m195. Leukemia 3 (1989) 339-348
7. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 (2005) 176-182
8. Vitale C., Romagnani C., Puccetti A., et al. Surface expression and function of p75/airm-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A 98 (2001) 5764-5769
9. Balaian L., Zhong R.K., and Ball E.D. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 31 (2003) 363-371
10. Balaian L., and Ball E.D. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol 33 (2005) 199-211
11. Hamann P.R., Hinman L.M., Hollander I., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13 (2002) 47-58
12. Larson R.A., Boogaerts M., Estey E., et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16 (2002) 1627-1636
13. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
14. + acute myeloid leukemia. Blood 106 (2005) 1183-1188
15. Virgo P., Denning-Kendall P.A., Erickson-Miller C.L., et al. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias. Br J Haematol 123 (2003) 420-430
16. Sundstrom C., and Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (u-937). Int J Cancer 17 (1976) 565-577
17. Li N., Zhang W.P., Wan T., et al. Cloning and characterization of Siglec-10, a novel sialic acid binding member of the IG superfamily, from human dendritic cells. J Biol Chem 276 (2001) 28106-28112
18. Munday J., Kerr S., Ni J., et al. Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem J 355 (2001) 489-497
19. Kikly K.K., Bochner B.S., Freeman S.D., et al. Identification of saf-2, a novel Siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol 105 (2000) 1093-1100
20. Caron P.C., Co M.S., Bull M.K., Avdalovic N.M., Queen C., and Scheinberg D.A. Biological and immunological features of humanized m195 (anti-CD33) monoclonal antibodies. Cancer Res 52 (1992) 6761-6767
21. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (cma-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
22. Kohls M.D., and Lappi D.A. Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. Biotechniques 28 (2000) 162-165
23. Ball E.D., Schwarz L.M., and Bloomfield C.D. Expression of the CD15 antigen on normal and leukemic myeloid cells: effects of neuraminidase and variable detection with a panel of monoclonal antibodies. Mol Immunol 28 (1991) 951-958
24. van der Velden V.H., Boeckx N., Jedema I., et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18 (2004) 983-988
25. Walter R.B., Raden B.W., Kamikura D.M., Cooper J.A., and Bernstein I.D. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105 (2005) 1295-1302
26. Jedema I., Barge R.M., van der Velden V.H., et al. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18 (2004) 316-325
27. Ball E.D., Vredenburgh J.J., Mills L.E., et al. Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies. Bone Marrow Transplant 6 (1990) 277-280
28. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., and Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 131 (2003) 254-263
29. Komba S., Werdelin O., Jensen T., and Meldal M. Synthesis of tumor associated sialyl-T-glycopeptides and their immunogenicity. J Pept Sci 6 (2000) 585-593
30. Julien S., Adriaenssens E., Ottenberg K., et al. St6Galnac I expression in mda-mb-231 breast cancer cells greatly modifies their o-glycosylation pattern and enhances their tumourigenicity. Glycobiology 16 (2006) 54-64
31. Rughetti A., Pellicciotta I., Biffoni M., et al. Recombinant tumor-associated muc1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174 (2005) 7764-7772
32. Miyagi T., Wada T., Yamaguchi K., and Hata K. Sialidase and malignancy: a minireview. Glycoconj J 20 (2004) 189-198